Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-AAT in alpha-1 antitrypsin deficiency
NL-OMON44026Phase 1Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing ARC-AAT with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started Jan 2016; status: active, not recruiting.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NL-OMON44026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44026.